Europese Unie - Nederlands - EMA (European Medicines Agency)

pfizer europe ma eeig - tofacitinib - artritis, reumatoïde - immunosuppressiva - rheumatoid arthritistofacitinib in combination with methotrexate (mtx) is indicated for the treatment of moderate to severe active rheumatoid arthritis (ra) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drugs (dmards) (see section 5. tofacitinib can be given as monotherapy in case of intolerance to mtx or when treatment with mtx is inappropriate (see sections 4. 4 en 4. psoriatic arthritistofacitinib in combination with mtx is indicated for the treatment of active psoriatic arthritis (psa) in adult patients who have had an inadequate response or who have been intolerant to a prior disease modifying antirheumatic drug (dmard) therapy (see section 5. ulcerative colitistofacitinib is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent (see section 5. tofacitinib is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (rheumatoid factor positive [rf+] or negative [rf-] polyarthritis and extended oligoarthritis), and juvenile psoriatic arthritis (psa) in patients 2 years of age and older, who have responded inadequately to previous therapy with disease modifying antirheumatic drugs (dmards). tofacitinib can be given in combination with methotrexate (mtx) or as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. ankylosing spondylitistofacitinib is indicated for the treatment of adult patients with active ankylosing spondylitis (as) who have responded inadequately to conventional therapy.

Europese Unie - Nederlands - EMA (European Medicines Agency)

pfizer limited - tofacitinib - artritis, reumatoïde - immunosuppressiva - de behandeling van reumatoïde artritis.

Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

aurobindo pharma b.v. baarnsche dijk 1 3741 ln baarn - fluconazol 150 mg/stuk - capsule, hard - gelatine (e 441) ; ijzeroxide geel (e 172) ; lactose 1-water ; magnesiumstearaat (e 470b) ; maÏszetmeel ; natriumlaurilsulfaat ; propyleenglycol (e 1520) ; schellak (e 904) ; siliciumdioxide (e 551) ; titaandioxide (e 171), gelatine (e 441) ; ijzeroxide geel (e 172) ; lactose 1-water ; magnesiumstearaat (e 470b) ; maÏszetmeel ; natriumlaurilsulfaat (e 487) ; propyleenglycol (e 1520) ; schellak (e 904) ; siliciumdioxide (e 551) ; titaandioxide (e 171), - fluconazole

Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

aurobindo pharma b.v. baarnsche dijk 1 3741 ln baarn - fluconazol 200 mg/stuk - capsule, hard - gelatine (e 441) ; ijzeroxide geel (e 172) ; lactose 1-water ; magnesiumstearaat (e 470b) ; maÏszetmeel ; natriumlaurilsulfaat ; propyleenglycol (e 1520) ; schellak (e 904) ; siliciumdioxide (e 551) ; titaandioxide (e 171), gelatine (e 441) ; ijzeroxide geel (e 172) ; lactose 1-water ; magnesiumstearaat (e 470b) ; maÏszetmeel ; natriumlaurilsulfaat (e 487) ; propyleenglycol (e 1520) ; schellak (e 904) ; siliciumdioxide (e 551) ; titaandioxide (e 171), - fluconazole

Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

aurobindo pharma b.v. baarnsche dijk 1 3741 ln baarn - fluconazol 50 mg/stuk - capsule, hard - gelatine (e 441) ; ijzeroxide geel (e 172) ; lactose 1-water ; magnesiumstearaat (e 470b) ; maÏszetmeel ; natriumlaurilsulfaat ; propyleenglycol (e 1520) ; schellak (e 904) ; siliciumdioxide (e 551) ; titaandioxide (e 171), gelatine (e 441) ; ijzeroxide geel (e 172) ; lactose 1-water ; magnesiumstearaat (e 470b) ; maÏszetmeel ; natriumlaurilsulfaat (e 487) ; propyleenglycol (e 1520) ; schellak (e 904) ; siliciumdioxide (e 551) ; titaandioxide (e 171), - fluconazole

Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

centrafarm b.v. van de reijtstraat 31-e 4814 ne breda - fluconazol 150 mg/stuk - capsule, hard - gelatine (e 441) ; lactose 1-water ; magnesiumstearaat (e 470b) ; siliciumdioxide (e 551) ; starch, pregelatinised (not from wheat starch) ; titaandioxide (e 171), - fluconazole

Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

dr. fisher farma b.v. - fluconazol; - poeder voor orale suspensie - fluconazole

Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

dr. fisher farma b.v. - fluconazol - poeder voor orale suspensie - citroenzuur 0-water (e 330) ; maltodextrine ; natriumbenzoaat (e 211) ; natuurlijk sinaasappelsmaakstof 57.458/ap 05.51 firmenich ; saccharose ; siliciumdioxide (e 551) ; titaandioxide (e 171) ; trinatriumcitraat 2-water (e 331) ; xanthaangom (e 415), - fluconazole

Europese Unie - Nederlands - EMA (European Medicines Agency)

eli lilly nederland b.v. - mirikizumab - colitis, ulcerative - immunosuppressiva - omvoh is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic treatment.

Europese Unie - Nederlands - EMA (European Medicines Agency)

eli lilly nederland b.v. - baricitinib - artritis, reumatoïde - immunosuppressiva - rheumatoid arthritisbaricitinib is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs (dmards). olumiant kan als monotherapie of in combinatie met methotrexaat worden gebruikt. atopic dermatitisolumiant is indicated for the treatment of moderate to severe atopic dermatitis in adult and paediatric patients 2 years of age and older who are candidates for systemic therapy. alopecia areatabaricitinib is indicated for the treatment of severe alopecia areata in adult patients (see section 5. juvenile idiopathic arthritisbaricitinib is indicated for the treatment of active juvenile idiopathic arthritis in patients 2 years of age and older who have had an inadequate response or intolerance to one or more prior conventional synthetic or biologic dmards:- polyarticular juvenile idiopathic arthritis (polyarticular rheumatoid factor positive [rf+] or negative [rf-], extended oligoarticular),- enthesitis related arthritis, and- juvenile psoriatic arthritis. baricitinib may be used as monotherapy or in combination with methotrexate.